Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 16Recruiting 6Terminated 4Active not recruiting 3Withdrawn 1Unknown 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Myeloid, Acute 2Neoplasm, Residual 1Myelodysplastic Syndromes 1Multiple Myeloma 1Hematologic Neoplasms 1

Interventions

fludarabine phosphate 2Tacrolimus 2Cyclophosphamide 2vactosertib 1aldesleukin 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Melphalan 1Interleukin-2 1IL32 protein, human 1Fibroblast Growth Factor 7 1Etoposide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Hematologic Neoplasms × Melphalan × Clear all
NCT02333162 2026-03-30

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

University of Chicago

Phase 1 Suspended
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡